Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michele Merli

Showing results (91-100 of 117) with videos related to

Pageof 12
Sort By:
Hemasphere|November 16, 2020
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid LeukemiaDiletta Fontana, Daniele Ramazzotti, Andrea Aroldi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2023
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular LymphomaPier Luigi Zinzani, Jiří Mayer, Christopher R Flowers, et al.
The Oncologist|December 16, 2018
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell LymphomasMichele Merli, Marco Frigeni, Laurent Alric, et al.
Haematologica|April 1, 2025
<i>Erratum</i> to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II studyEmilio Iannitto, Simone Ferrero, Côme Bommier, et al.
American Journal of Hematology|October 8, 2019
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC groupBarbara Mora, Paola Guglielmelli, Elisa Rumi, et al.
Haematologica|March 18, 2024
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II studyEmilio Iannitto, Simone Ferrero, Côme Bommier, et al.
Hematological Oncology|May 13, 2025
Comparative Effectiveness of R-miniCOMP Versus R-miniCHOP in Older Non-Fit Patients With Diffuse Large B-Cell Lymphoma: Insights From a "Fondazione Italiana Linfomi" Cohort StudyAlberto Bavieri, Sara Veronica Usai, Michele Merli, et al.
The New England Journal of Medicine|December 30, 2025
Direct-Acting Antiviral Agents in Hepatitis C-Associated Indolent LymphomasMichele Merli, Elisa Genuardi, Silvia Zibellini, et al.
British Journal of Haematology|November 9, 2018
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 studyEmilio Iannitto, Monica Bellei, Sandy Amorim, et al.
Blood Advances|January 14, 2025
Large clones of clonal hematopoiesis affect outcome in mantle cell lymphoma: results from the FIL MCL0208 clinical trialSimone Ragaini, Anna Galli, Elisa Genuardi, et al.
Pageof 12

Showing results (91-100 of 117) with videos related to

Sort By:
Pageof 12
Hemasphere|November 16, 2020
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid LeukemiaDiletta Fontana, Daniele Ramazzotti, Andrea Aroldi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2023
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular LymphomaPier Luigi Zinzani, Jiří Mayer, Christopher R Flowers, et al.
The Oncologist|December 16, 2018
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell LymphomasMichele Merli, Marco Frigeni, Laurent Alric, et al.
Haematologica|April 1, 2025
<i>Erratum</i> to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II studyEmilio Iannitto, Simone Ferrero, Côme Bommier, et al.
American Journal of Hematology|October 8, 2019
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC groupBarbara Mora, Paola Guglielmelli, Elisa Rumi, et al.
Haematologica|March 18, 2024
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II studyEmilio Iannitto, Simone Ferrero, Côme Bommier, et al.
Hematological Oncology|May 13, 2025
Comparative Effectiveness of R-miniCOMP Versus R-miniCHOP in Older Non-Fit Patients With Diffuse Large B-Cell Lymphoma: Insights From a "Fondazione Italiana Linfomi" Cohort StudyAlberto Bavieri, Sara Veronica Usai, Michele Merli, et al.
The New England Journal of Medicine|December 30, 2025
Direct-Acting Antiviral Agents in Hepatitis C-Associated Indolent LymphomasMichele Merli, Elisa Genuardi, Silvia Zibellini, et al.
British Journal of Haematology|November 9, 2018
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 studyEmilio Iannitto, Monica Bellei, Sandy Amorim, et al.
Blood Advances|January 14, 2025
Large clones of clonal hematopoiesis affect outcome in mantle cell lymphoma: results from the FIL MCL0208 clinical trialSimone Ragaini, Anna Galli, Elisa Genuardi, et al.
Pageof 12